TauRx was established to address one of the world’s biggest challenges – beating Alzheimer’s disease and other degenerative b ... rain disorders through a completely new approach. A leader in Alzheimer’s research, the company’s mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative disorders. TauRx’s strong research team, supported through cooperative relationships with multiple academic institutions around the world, has focussed on the tau pathway, believed to be one of the critical causes of neurodegeneration in the brain. The company’s novel tau aggregation inhibitors (TAIs) target the formation of tau protein ‘tangles’ in the brain, with its lead compound having shown strong pharmacological effect in trial participants with mild and moderate Alzheimer's disease. The experimental drug has shown to inhibit aggregation of tau, synuclein, TPD-43 and huntingtin proteins. It is currently in development for the treatment and prevention of Alzheimer’s disease, with a pivotal phase 3 clinical trial underway. A further late stage trial is planned for development of the drug for behavioural variant Frontotemporal Dementia. Additionally, TauRx works closely with joint venture company Genting TauRx Diagnostics Ltd (GTD) in the development of ground-breaking new diagnostic tools and blood tests for dementia, which will help transform the treatment pathway for those affected, ensure efficient and early diagnosis and enhance access to treatment and care. TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland. read more